IL37 and neoplasm: We are constantly discussing evidence-based medicine in this context as well, and, just as we suggested above, both the clinical trials conducted so far and the meta-analyses, the data from international registers, and, last but not least, the clinical experience of specialists are the powerful tools that we have at hand when we make the claim that so far there are no data to show that anti-TNF-α and anti-IL-23 therapies would be directly criminalized in the induction of neoplasia, be they organ or hematological.